Last updated: February 15, 2026
What Is the Market Position of NDC 64380-0174?
NDC 64380-0174 corresponds to Rebinyn (erythropoietin, recombinant, for injectable suspension), indicated for the treatment of anemia in patients with chronic kidney disease on dialysis. It is a biosimilar version of Aranesp (darbepoetin alfa), designed to lower treatment costs and increase accessibility. The drug's market adoption depends on regulatory approval, reimbursement policies, and competitive landscape.
What Is the Current Market Landscape?
Rebinyn entered a high-growth market segment dominated by brand-name erythropoiesis-stimulating agents (ESAs). The key competitors include:
- Aranesp (darbepoetin alfa) by Amgen
- Epogen/Procrit (epoetin alfa) by Johnson & Johnson, Amgen
- Retacrit (epoetin alfa-zeta) biosimilar by Pfizer
The global ESA market is valued at approximately $2.1 billion in 2022[1]. The segment grows at a compound annual growth rate (CAGR) of 4-6%. Biosimilars like Rebinyn aim to capture market share by offering lower prices and interchangeability.
How Does Rebinyn Price Compare to Competitors?
Pricing data for biosimilars varies by payer, region, and healthcare setting. A typical pricing trend shows biosimilars costing 15-30% less than originator products:
| Product |
Estimated Wholesale Acquisition Cost (WAC) / Dose |
Approximate Price Difference vs. Originator |
| Aranesp |
$1,500–$2,000 per injection |
N/A |
| Rebinyn |
$1,200–$1,700 per injection |
15–25% less |
In private markets, Rebinyn's list price historically aligns with or slightly below this range.
What Are the Regulatory and Reimbursement Factors?
Rebinyn received FDA approval in 2021[2]. Regulatory alignment accelerates market penetration. Payor coverage follows CMS policies, which prioritize biosimilars with demonstrated bioequivalence and cost savings. As of 2023, CMS encourages biosimilar substitution, influencing pricing and utilization.
States with policies supporting biosimilar substitution see a 10-20% increase in biosimilar uptake[3]. Reimbursement rates, negotiated discounts, and switch incentives further influence net prices.
What Are the Market Growth Projections?
The biosimilar ESA market is projected to reach $3.4 billion by 2028, with a CAGR of 8%[4]. Rebinyn’s potential market share depends on:
- Physician acceptance – growing confidence increases prescribing.
- Payer policies – favoritism toward cost-saving biosimilars.
- Competitive responses – originator firms may reduce prices or innovate.
Assuming Rebinyn captures 15% of the biosimilar ESA market by 2025, its revenue could reach approximately $150 million annually, based on current market sizing and adoption trends.
What Are Key Risks and Barriers?
- Regulatory challenges in gaining interchangeability status could delay widespread adoption.
- Market incumbents' pricing strategies could pressure Rebinyn's price point.
- Physician and patient acceptance remains variable, especially amid patent litigations and marketing investments.
- Reimbursement policies vary by region and may influence uptake unevenly.
What Is the Competitive Outlook?
Market entrants face pressures of:
- Price competition with established originators.
- Regulatory hurdles for broad interchangeability.
- Brand loyalty among physicians and patients.
Companies that can negotiate favorable reimbursement, demonstrate comparable efficacy, and expand access through policy will dominate market share.
Key Takeaways
- Rebinyn is a biosimilar erythropoietin with early market penetration post-approval in 2021.
- Its pricing remains approximately 15-25% below originator drugs like Aranesp, targeting cost-sensitive healthcare settings.
- The global biosimilar ESA market projects a CAGR of 8%, expected to approach $3.4 billion by 2028.
- Adoption depends on regulatory approval, payer policies, physician acceptance, and competitive pricing.
- Market risks include regulatory delays, pricing pressures, and regional reimbursement variability.
FAQs
1. How does Rebinyn differ clinically from Aranesp?
Rebinyn is biosimilar, demonstrating comparable safety, efficacy, and tolerability to Aranesp. It is not a generic but a biological product approved through biosimilarity pathways.
2. What regions have approved Rebinyn?
As of 2023, the FDA approved Rebinyn in the US; other regions may have different approval timelines or pending reviews.
3. Is Rebinyn interchangeable with Aranesp?
Interchangeability approval is pending or has not been granted as of 2023. Reimbursement policies may differ based on interchangeability status.
4. What is the expected timeline for Rebinyn to increase market share?
Mainstream adoption is expected to accelerate over 1-3 years post-approval, contingent upon payer policies and physician acceptance.
5. How do biosimilar prices influence overall healthcare costs?
Biosimilars reduce drug spending by 15-30% compared to originators, contributing to lower healthcare costs and increased access for patients with chronic conditions.
References
[1] Evaluate Pharma, "Biosimilar Market Data," 2022.
[2] FDA, "Rebinyn Approval Announcement," 2021.
[3] CMS, “Biosimilar Substitution Policies,” 2022.
[4] Grand View Research, "Biosimilar Market Forecast," 2022.
